About KBL
KBL is a venture capital firm founded in 1991. It is primarily based out of New York City, United States. As of Jun 2017, KBL has invested in 13 companies. It primarily invests in Series D round in United States based startups. Its investments are spread across Life Sciences and Consumer sectors. Most recently it participated in the $***** Series G round of NeuroStar Overall, KBL portfolio has seen 2 IPOs and 6 acquisitions including key companies like Scynexis, NeuroStar and ISTA Pharmaceuticals. A lot of funds co-invest with KBL, with names like Accuitive Medical Ventures sharing a substantial percentage of its portfolio. KBL has team of 11 people including 1 partners.Key Metrics
Team Members
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series C, PE & 4 more
Portfolio Acquisitions
Portfolio Soonicorns
KBL's List of Top Investments
KBL has a portfolio of 13 companies. Their most notable investments are in CardioFocus and Scynexis.Their portfolio spans across United States and Israel. They have invested in Life Sciences, Consumer, across Series C, PE and 4 more. Here is the list of top investments by KBL:1. Scynexis
Developing glucan synthase inhibitors for the treatment of fungal infections. The company's lead candidate is SCY-078, which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections. SCY-078 acts as a glucan synthase inhibitor against a broad range of Candida and Aspergillus species.
Key facts about Scynexis
- Founded Year: 1999
- Location: Jersey City (United States)
- Annual Revenue: $10M - $50M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $62.7M
- Employee Count: 50 as on Jul 31, 2026
- Investors: Foresite Capital, KBL and 14 Others
- Latest Funding Round: Post IPO, Apr 09, 2020, $*****
- Highlight: Public
2. NeuroStar
Provider of a non-drug non-invasive therapeutic devices for neurorehabilitation. It focuses on the therapeutic applications of the MRI-strength pulsed magnetic field for treating disorders of the central nervous system. The TMS Therapy is an FDA cleared device used for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.
Key facts about NeuroStar
- Founded Year: 2003
- Location: Malvern (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $119M
- Employee Count: 202 as on Jul 31, 2026
- Investors: Quaker Partners Management, New Leaf Venture Partners and 14 Others
- Latest Funding Round: Conventional Debt, Mar 02, 2020, $*****
- Highlight: Public
3. Neuronetics
Transforming neurohealth with innovative, non-drug TMS therapy for mental health. The company is dedicated to improving the lives of individuals suffering from psychiatric disorders by offering patient-centric medical devices. They specialize in transcranial magnetic stimulation (TMS) treatment, providing a non-drug, non-invasive alternative for those with depression and OCD. Committed to practice success, they offer ongoing support and strive to expand their capabilities to cover additional indications. Their approach focuses on compassion, innovation, and growth, aiming to provide a safe, effective, and durable treatment option. They are committed to compliance and ethical practices, ensuring the highest quality of care for both patients and healthcare providers.
Key facts about Neuronetics
- Founded Year: 2001
- Location: Malvern (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2025
- Stage: Series G
- Total Funding till date: $178M
- Employee Count: 216 as on Mar 31, 2026
- Investors: Western Technology Investment, Quaker Partners Management and 16 Others
- Latest Funding Round: Series G, Jun 06, 2017, $*****
4. CardioFocus
CardioFocus is a medical device company focused on improving ablation treatment for atrial fibrillation. Its solution, the HeartLight Endoscopic Ablation System incorporates an endoscope to view the internal parts of the heart and visually direct laser energy to achieve durable pulmonary vein isolation. Its products are available throughout Europe and Australia. It is approved by FDA.
Key facts about CardioFocus
- Founded Year: 1990
- Location: Marlborough (United States)
- Stage: Series E
- Total Funding till date: $261M
- Employee Count: 87 as on Jul 31, 2026
- Investors: Western Technology Investment, Saints Capital and 22 Others
- Latest Funding Round: Series E, Feb 23, 2023, $*****
- Highlight: Editors' Pick
ISTA Pharmaceuticals offers prescription eye care in the US with an expanding focus on allergy therapeutics. Currently markets four products, including treatments for ocular inflammation and pain post-cataract surgery, glaucoma and ocular itching associated with allergic conjunctivitis. The company's development pipeline contains additional candidates in various stages of development to treat dry eye, ocular inflammation and pain, and nasal allergies. The company generated revenues of $160 million in 2011. Was acquired by Bausch and Lomb in Mar 2012. In July 2013, Bausch and Lomb was acquired by Valeant.
Key facts about ISTA Pharmaceuticals
- Founded Year: 1992
- Location: Irvine (United States)
- Stage: Acquired
- Total Funding till date: $149M
- Employee Count: 168 as on May 31, 2026
- Investors: New Leaf Venture Partners, Domain Associates and 10 Others
- Latest Funding Round: PE, Sep 26, 2008, $*****
- Highlight: Acquired
KBL's Year-on-Year Investment Trends
KBL has invested in 13 companies over the last 26 years, with an average of 0 new investment annually in the last 10 years. Its most recent first time investment was in NeuroStar and most recent follow-on round was in Neuronetics.KBL's Investments by Stage
KBL is primarily an Late Stage Investor investor majorly investing in Series C (3) rounds where average round size is $88.5M, PE (2) rounds where average round size is $110M and Series B (2) rounds where average round size is $61M.Stage of entry | No. of Investments |
|---|---|
Series C | 3 |
PE | 2 |
Series B | 2 |
Series D | 2 |
Series E | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
KBL's Investments by Sector
KBL has a diverse portfolio, with companies operating in the Life Sciences, Consumer and Sustainability Tech. Notably, it has invested in 11 Enterprise (B2B) companies, 9 Tech companies, 2 Consumer (B2C) companies and at least 2 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 9 |
Consumer | 2 |
Sustainability Tech | 2 |
Note: We have considered here, only first round of investments
KBL's Investments by Geography
KBL has made most investments in United States (10), followed by Israel where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 10 |
Israel | 1 |
Note: We have considered here, only first round of investments
KBL's recent investments
KBL has not made any investment in 2026 so far.Here are the most recent investments by KBL:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jun 13, 2017 | United States | Series G | 2321 | [+10] | |
Jun 06, 2017 | United States | Series G | 5266 | [+10] | |
Dec 19, 2011 | United States | Conventional Debt | 6951 | [+3] | |
Dec 12, 2011 | United States | Series D | 7393 | [+3] | |
Feb 28, 2011 | United States | Series D | 2571 |
IPOs and Publicly Listed companies in KBL's Portfolio
2 of KBL's portfolio companies have become public. NeuroStar got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Jun 2018 at marketcap of $285M and Scynexis got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $84.5M.Here are KBL's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jun 28, 2018 | Jun 13, 2017 | Series G | 5503 | |
May 02, 2014 | Dec 12, 2011 | Series D | 6204 |
Acquired companies in KBL's Portfolio
6 companies from KBL's portfolio have been acquired. The most recent acquisition was Achillion in Oct 2019 by Alexion for $*****.Here are KBL's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Oct 16, 2019 | Jan 28, 2002 | Series C | 7620 | |
Mar 24, 2016 | - | - | 1641 | |
Dec 04, 2014 | Mar 05, 2007 | Series B | 9870 | |
Mar 26, 2012 | Nov 19, 2002 | PE | 6215 | |
Jun 03, 2007 | Dec 27, 2004 | Series C | 6532 |
Team profile of KBL
KBL has a team of 11 members located in United States. KBL's team does not sit on the board of any company as of now.Co-investors of KBL
Over the past 26 years, 87 investors have co-invested in KBL's portfolio companies. This includes only funds.
- Invested before KBL: IRS, Alta Partners and 15 others have invested in rounds before KBL. There is 1 company where IRS has invested before KBL and 1 company where Alta Partners has invested before KBL.
- Top Co-investors of KBL: 47 investors entered a company along with KBL. These include investors like Accuitive Medical Ventures (2 companies).
- Invested after KBL: A total of 23 investors have invested in KBL's portfolio after their investments. Top Investors include SVB (2 companies), SLR Investment Corp (1 company) and Puissance Capital (1 company).
Recent News related to KBL
•
Medical device company Neuronetics pulls in $15 mlnPE Hub•Jun 06, 2017•NeuroStar, Neuronetics, Ascension Ventures, Accuitive Medical Ventures and 10 others
•
New Leaf Venture Partners Leads $30 Million Financing in Neuronetics | Business WireBusiness Wire•Sep 02, 2009•Neuronetics, New Leaf Venture Partners, Three Arch Partners, ONSET Ventures and 4 others
•
Achillion Pharmaceuticals Raises $41 Million In A Private PlacementPR Newswire•Jan 28, 2002•Achillion, Bear Stearns Companies, Advent International, Atlas Venture and 6 others
